⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22104 | 1.00 | — | — | |
| Hydrogen Sulfide SCHEMBL6714329 | 0.96 | — | — | |
| SCHEMBL2936884 | 0.78 | — | — | |
| SCHEMBL31558674 | 0.76 | — | — | |
| SCHEMBL2943905 | 0.73 | — | — | |
| SCHEMBL9017826 | 0.73 | — | — | |
| SCHEMBL8456496 | 0.73 | — | — | |
| SCHEMBL8375109 | 0.73 | — | — | |
| SCHEMBL2839857 | 0.73 | — | — | |
| SCHEMBL2839859 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067603-B2 | Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-29 | — | — | US | claimed |
| US-7851630-B2 | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-12-14 | — | — | US | claimed |
| EP-1694675-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORLI RECEPTORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-30 | — | — | EP | claimed |
| EP-1664017-A1 | BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2006-06-07 | — | — | EP | claimed |
| WO-2005058890-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | WO | claimed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | claimed |
| US-20050075355-A1 | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. | 2005-04-07 | — | — | US | claimed |
| US-20050070528-A1 | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. | 2005-03-31 | — | — | US | claimed |
| WO-2005028466-A1 | BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-03-31 | — | — | WO | claimed |
| US-8067603-B2 | Opiod receptor-like receptors (ORL1); for treatment of chronic pain conditions, central nervous system disorders such as anxiety and stress disorders, depression, epilepsy, stroke, Alzheimer's disease, eating disorders, and drug abuse | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-11-29 | — | — | US | disclosed |
| US-7851630-B2 | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-12-14 | — | — | US | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1694675-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORLI RECEPTORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1670457-A1 | BICYCL 3.1.1]HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | Solvay Pharmaceuticals B.V. (NL) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005058890-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
| WO-2005032547-A1 | BICYCLO`3.1.1!HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-04-14 | — | — | WO | disclosed |
| US-20050075355-A1 | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. | 2005-04-07 | — | — | US | disclosed |
| US-20050070528-A1 | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS B.V. | 2005-03-31 | — | — | US | disclosed |
| WO-2005028466-A1 | BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-03-31 | — | — | WO | disclosed |